News: CMN Weekly (22 October 2021)
Oct. 22, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Sana Biotechnology
Main focus: Cellular engineering for genetic diseases and cancer
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-Cas12b
Funding stage: Public (NASDAQ:SANA)
Location: Seattle, Washington, United States
Website: https://sana.com/
Pipeline: https://sana.com/our-science/
Partners: Beam Therapeutics
Sana Biotechnology is a Seattle-based company that focuses on the development of in vivo and ex vivo engineered cell therapies. Using its Fusogen technology platform, the company aims to create in vivo engineered CAR-T cells, which might circumvent many of the obstacles associated with conventional CAR-T cell therapies. Likewise, the company's Hypoimmune technology is being applied for the development of ex vivo engineered donor- and stem cell-derived cellular therapies. The company has obtained licenses from Beam Therapeutics to use the CRISPR-Cas12b system as part of a number of its ex vivo engineered cell programmes.
